S-1 + gefitinib

S-1 + gefitinib is a combination therapy consisting of the oral fluoropyrimidine derivative S-1 and the EGFR tyrosine kinase inhibitor gefitinib. This combination has been studied primarily for treating non-small cell lung cancer (NSCLC), particularly in cases with EGFR mutations and acquired resistance to EGFR-TKIs. The combination works through dual mechanisms: gefitinib inhibits EGFR tyrosine kinase activity, blocking downstream signaling cascades that promote cancer cell survival, while S-1 (containing tegafur, gimeracil, and oteracil) provides cytotoxic effects through its active metabolite 5-fluorouracil. Research suggests this combination may be particularly effective in overcoming resistance to EGFR-TKIs in NSCLC with MET amplification.

Brand names

TeysunoIressa

Other names

Tegafur/Gimeracil/Oteracil + GefitinibS-1 plus GefitinibS1 plus GefitinibS 1 plus Gefitinib